First-in-human, Two-stage, Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of AN3365 in Single and Multiple Doses in Young Healthy Subjects.

Trial Profile

First-in-human, Two-stage, Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of AN3365 in Single and Multiple Doses in Young Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Epetraborole (Primary)
  • Indications Gram-negative infections
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 05 Jun 2017 Results presented at the ASM Microbe 2017
    • 19 Apr 2011 Results will be presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases, according to a Anacor media release.
    • 15 Jun 2010 Tolerability data reported in Anacor media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top